Efficacy and Safety Study of Sodium Phosphate Tablets vs PEG for Bowel Cleansing

NCT ID: NCT01840553

Last Updated: 2014-03-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

461 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy and safety of sodium phosphate tablets compared to split dose of 4 liters of PEG used in adults for bowel cleansing prior to colonoscopy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colon Cleansing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

polyethylene glycol

4 Liters of PEG administered split in 2 doses

Group Type ACTIVE_COMPARATOR

polyethylene glycol

Intervention Type DRUG

oral sodium phosphate tablets

oral Sodium Phosphate tablets administered as 32 tablets (20+12) with 2 Liters of liquid

Group Type EXPERIMENTAL

oral sodium phosphate tablets

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

oral sodium phosphate tablets

Intervention Type DRUG

polyethylene glycol

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged from 18 to 75 years (included).
* Scheduled for a colonoscopy as an outpatient.
* Normal renal function

Exclusion Criteria

* Having a disease or condition as follows:

* repeated episodes of nausea and vomiting
* abdominal pain due to severe infection or requiring surgery
* clinically significant abnormal electrolytes values
* congestive heart failure, unstable angina pectoris or recent myocardial infarction, percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass surgery within previous 3 months
* known/suspected bowel obstruction, megacolon, ileus or intestinal perforation, or gastroparesis,
* inflammatory bowel disease,
* history of gastric stapling or bypass procedure or gastric retention
* Sodium phosphate preparation taken within the past three weeks prior to colonoscopy.
* Known allergy to any of the active ingredients or excipients of the study drugs.
* History of phenylketonuria
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Laboratoires Mayoly Spindler

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Avicenne

Bobigny, , France

Site Status

Polyclinique Bordeaux Nord Aquitaine

Bordeaux, , France

Site Status

Hopital Edouard Herriot

Lyon, , France

Site Status

Groupe Hospitalier Intercommunal Le Raincy-Montfermeil

Montfermeil, , France

Site Status

CHU Hotel Dieu

Nantes, , France

Site Status

Hopital l'Archet

Nice, , France

Site Status

CHU Cochin

Paris, , France

Site Status

Clinique Saint-Jean Languedoc

Toulouse, , France

Site Status

Sana Klinikum Lichtenberg

Berlin, , Germany

Site Status

Kreisklinik Biberach

Biberach, , Germany

Site Status

Klinikum Heidenheim

Heidenheim, , Germany

Site Status

Medizinische Klinik und Poliklinik II Munchen

München, , Germany

Site Status

Complejo Hospitalario de A Coruna

A Coruña, , Spain

Site Status

Hospital Clinic de Barcelona

Barcelona, , Spain

Site Status

Hospital de Fuenlabrada

Fuenlabrada, , Spain

Site Status

Hospital 12 de Octubre

Madrid, , Spain

Site Status

Hospital Clinico San Carlos

Madrid, , Spain

Site Status

Hospital Universitarion Gregorio Maranon

Madrid, , Spain

Site Status

Clinica Universidad de Navarra

Pamplona, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France Germany Spain

References

Explore related publications, articles, or registry entries linked to this study.

Chaussade S, Schmocker C, Toulemonde P, Munoz-Navas M, O'Mahony V, Henri F. Phosphate tablets or polyethylene glycol for preparation to colonoscopy? A multicentre non-inferiority randomized controlled trial. Surg Endosc. 2017 May;31(5):2166-2173. doi: 10.1007/s00464-016-5214-1. Epub 2016 Nov 18.

Reference Type DERIVED
PMID: 27864718 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012-005115-13

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ICOL121

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.